GSK's Hal Bar­ron ax­es a once-prized drug from J&J, con­tin­u­ing shift away from res­pi­ra­to­ry

Hal Bar­ron’s re­vamp of the Glax­o­SmithK­line pipeline con­tin­ued yes­ter­day, as the British phar­ma an­nounced they axed an asth­ma drug they once promised over $200 mil­lion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER